Crizotinib must be administered orally, in fact it is formulated in the form of hard capsules. In Italy, it is available in a "unique medicinal product with the trade name Xalkori® and available in two different dosages (200 mg and 250 mg). These are hospital drugs (range H) available in pharmacies upon presentation of a non-prescription medical prescription. repeatable limitative (RNRL - drugs that can be sold to the public on prescription from hospitals or specialists).
non-small cell lung disease that has a specific rearrangement or defect in the ALK (anaplastic lymphoma kinase) gene, or the ROS1 gene.
Crizotinib can be prescribed as an initial treatment if the cancer is advanced, as well as it can be prescribed to treat those advanced cancers for which previous treatments have not been shown to stop the progression of the disease.
, as some disorders may worsen when treated with crizotinib. The active ingredient, in fact, can cause lung inflammation during treatment.During treatment with crizotinib, however, the doctor should be advised immediately if:
- New symptoms appear or those already present worsen, including difficulty in breathing, shortness of breath, cough with or without mucus or fever, as this could be lung inflammation.
- You feel severe abdominal pain and if you experience fever, chills, shortness of breath, fast heart rate, partial or complete loss of vision (in one or both eyes), or changes in bowel habits.
